YKL-5-124 TFA |
| Catalog No.GC39462 |
YKL-5-124 TFA es un inhibidor de CDK7 potente, selectivo, irreversible y covalente con IC50 de 53,5 nM y 9,7 nM para CDK7 y CDK7/Mat1/CycH, respectivamente. YKL-5-124 TFA es >100 veces mÁs selectivo para CDK7 que para CDK9 y CDK2, e inactivo contra CDK12 y CDK13. YKL-5-124 TFA induce una fuerte detenciÓn del ciclo celular, inhibe la expresiÓn génica impulsada por E2F y muestra poco efecto sobre el estado de fosforilaciÓn de la ARN polimerasa II.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2748220-93-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selectivity for CDK7 than CDK9 and CDK2 and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, and inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status[1].
[1]. Olson CM, et al. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chem Biol. 2019 Jun 20;26(6):792-803.e10.
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *